In vitro evaluation of temozolomide combined with X-irradiation

Anti-Cancer Drugs

Volumn 8, Issue 1, 1997, Pages 92-97

  Wedge, Stephen R ^a   Porteous, Julia K ^a   Glaser, Mark G ^a   Marcus, Kim ^a   Newlands, Edward S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

cytotoxicity; glioma; isobologram; O6 benzylguanine; radiotherapy; temozol omide

Indexed keywords

6 O BENZYLGUANINE; TEMOZOLOMIDE;

ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE; X RAY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DNA ADDUCTS; DNA REPAIR; GLIOBLASTOMA; HUMANS; METHYLTRANSFERASES; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR CELLS, CULTURED;

EID: 0031052506     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199701000-00013     Document Type: Article

References (34)

1. Gaspar LE, Fisher BJ, MacDonald DR, et al. Malignant glioma - timing of response to radiation therapy. Int J Radiat Oncol Biol Phys 1993; 25: 877-9.
2. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Cancer 1996; 77: 1535-43.
3. Newlands ES, Blackledge GRP, Slack JA, et al. Phase I trial of temozolomide (CCRG 81046: M & B 39831: NSC 36286). Br J Cancer 1992; 65: 287-91.
4. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide a new oralcytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29A: 940-2.
5. Margison GP, O'Connor PJ. Biological consequences of reactions with DNA: role of specific lesions. Chemical carcinogenisis and mutagenesis. In: Grover PL, Phillips DH, eds. Handbook of experimental chemotherapy Heidelberg: Springer 1990: 547-71.
6. 6-Methylguanine in DNA inhibits replication in vitro by human cell extracts. Biochemistry 1993; 32: 13664-72.
7. 6-Methylguanine residues elicit DNA repair synthesis by human cell extracts. J Biol Chem 1993; 268: 15878-86.
8. Stevens MFG, Hickman JA, Langdon SP et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazine-4(-3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-52.
9. Newlands ES, Rustin GJS, Evans H, Wedge SR, Brampton MH. Phase I trial of temozolomide administered over 6 and 7 weeks. Ann Oncol 1996; 7 (suppl 1): 345.
10. Nelson DF, Curran Jr WJ, Scott C, et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy B.I.D. fractions: report of the radiation therapy oncology group protocol 8302. Int J Radiat Oncol Biol Phys 1996; 25: 193-207.
11. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-29.
12. 6-benzylguanive: a comparative study in vitro. Br J Cancer 1996; 73: 482-90.
13. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 1996; 73: 1049-52.
14. O-alkylguanine DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells. Br J Cancer 1993: 67: 1299-302.
15. Skehan P, Storeng R, Scudiero D, et al. New colorimetric assay for anti-cancer drug screening. J Natl Cancer Inst 1990; 82: 1107-18.
16. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol 1979; 5: 85-91.
17. Okano T, Ohnuma T, Holland JF, et al. Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1. Invest New Drugs 1983; 1: 145-50.
18. Steel GG. Terminology of clinical combined radiotherapy-chemotherapy. Radiother Oncol 1988; 11: 31-53.
19. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71-85.
20. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-84.
21. 6-methylguanine by normal and transformed human cells. Proc Am Ass Cancer Res 1983; 24: 335-7.
22. 6-methylguanine-DNA methyltransferase activity in brain tumours and adjacent normal brain. Cancer Res 1993; 53: 3416-20.
23. 6-Methylguanine methyltransferase activity is increased in rat tissues by ionizing radiation. Carcinogenesis 1985; 6: 1699-702.
24. 6-alkylgua-nine-DNA-alkyltransferase in response to indium-114m. Radiat Res 1994; 138: 26-33
25. 6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene 1996; 12: 693-7.
26. 6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol 1991; 11: 4660-8.
27. 6-alkylguanine-DNA alkyltransferase activity in fetal rat brain and liver and the induction of CNS tumours. Carcinogenesis 1990; 11: 219-22.
28. Powell S, McMillan TJ. DNA damage and repair following treatment with ionizing radiation. Radiother Oncol 1990; 19: 95-108.
29. 6-alkylguanine-DNA alkyltransferase activity are equally sensitive to X-rays. Mutat Res 1992; 283: 125-9.
30. Van Meir EG, Kikuchi T, Tada M, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994; 54: 649-52.
31. Van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 Mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 1994; 86: 1011-7.
32. 6-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagen 1992; 7: 83-5.
33. Rasheed BKA, McLendon RE, Friedman HS, et al. Chromosone 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995; 10: 2243-6.
34. Newlands ES, O'Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996; in press.